Atenolol in hypertension: is it a wise choice?

@article{Carlberg2004AtenololIH,
  title={Atenolol in hypertension: is it a wise choice?},
  author={Bo Carlberg and Ola Samuelsson and Lars H. Lindholm},
  journal={The Lancet},
  year={2004},
  volume={364},
  pages={1684-1689}
}
BACKGROUND Atenolol is one of the most widely used beta blockers clinically, and has often been used as a reference drug in randomised controlled trials of hypertension. However, questions have been raised about atenolol as the best reference drug for comparisons with other antihypertensives. Thus, our aim was to systematically review the effect of atenolol on cardiovascular morbidity and mortality in hypertensive patients. METHODS Reports were identified through searches of The Cochrane… Expand
Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?
TLDR
This work considers the mechanisms which might be responsible for the inferiority of atenolol in preventing vascular morbidity and mortality in patients with primary hypertension and designs drugs that are not only more effective in achieving blood pressure targets but that also markedly decrease vascular events. Expand
Atenolol as a comparator in outcome trials in hypertension: A correct choice in the past, but not for the future?
TLDR
As the results of the LIFE study and other recent trials demonstrate superiority of newer agents over atenolol, this agent is not an appropriate reference drug for future trials of cardiovascular risk in hypertension. Expand
Should atenolol still be recommended as first-line therapy for primary hypertension?
TLDR
The aim of this study was to systematically review and analyse the effect of atenolol on cardiovascular and allcause mortality, stroke and myocardial infarction in hypertensive patients and to recommend newer vasodilating drugs, which have a more favorable haemodynamic profile, as more beneficial. Expand
Comparative Study of Atenolol And Nebivolol on Hypertension And Heart Rate in Hypertensive Patients
Hypertension is the leading cause of death and a major risk factor for cardiovascular diseases. Beta blockers play an important role in the reduction of both systolic and diastolic blood pressures.Expand
A comparison of atenolol and nebivolol in isolated systolic hypertension
TLDR
Nebivolol reduces aortic pulse pressure more than atenolol, which may be related to a less pronounced rise in AIx and bradycardia, and whether this will translate into differences in clinical outcome requires further investigation. Expand
Does atenolol differ from other β-adrenergic blockers?
TLDR
The claim that all β-adrenergic blockers are inferior drugs for hypertensive patients should be rejected and Atenolol is not representative of the β- adrenergic blocker class of drugs as a whole and is thus not a suitable drug for comparisons with other antihypertensive drugs in terms of effect. Expand
Efficacy and Tolerability of Nebivolol Compared with Other Antihypertensive Drugs
TLDR
Results of previous pharmacokinetic studies suggest that nebivolol 5 mg may not conform completely to the definition of a classic β-blocker demonstrating additional antihypertensive effect due to endothelial NO release-mediated vasodilation. Expand
Use of carvedilol in hypertension: an update
TLDR
The present report provides an overview of the main clinical studies concerning carvedilol administered as either monotherapy or in combination with another antihypertensive or more frequently a diuretic agent, with particular focus on the additional benefits beyond blood pressure reduction. Expand
Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis
TLDR
It is believed that beta blockers should not remain first choice in the treatment of primary hypertension and should not be used as reference drugs in future randomised controlled trials of hypertension. Expand
Nebivolol: its role in the treatment of hypertension and chronic heart failure
TLDR
In patients with hypertension, randomized, controlled trials demonstrated that the effects of nebivolol on reduction of blood pressure are at least similar when compared with other β-blockers. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.
TLDR
Total mortality was significantly lower for metoprolol than for thiazide diuretics because of fewer deaths from coronary heart disease and stroke and the benefit demonstrated in patients treated with metoprole seems to have important implications for clinical practice. Expand
beta-Blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension.
TLDR
The time has come to admit that beta-blockers should no longer be considered appropriate for first-line therapy in uncomplicated hypertension, due to a lack of efficacy and multiple adverse effects. Expand
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
TLDR
This study provided no evidence that either drug has any specific beneficial or deleterious effect, suggesting that blood pressure reduction in itself may be more important than the treatment used. Expand
Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.
TLDR
Antihypertensive treatment based on a beta-blocker or on a thiazide diuretic could not be shown to affect the prevention of hypertensive complications, including CHD, to a different extent. Expand
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
TLDR
Beta-blocker therapy had benefits for survival in stable heart-failure patients and should not be extrapolated to patients with severe class IV symptoms and recent instability because safety and efficacy has not been established in these patients. Expand
Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study
TLDR
Diltiazem was as effective as treatment based on diuretics, beta-blockers, or both in preventing the combined primary endpoint of all stroke, myocardial infarction, and other cardiovascular death. Expand
Randomised trial of treatment of hypertension in elderly patients in primary care.
A randomised trial of the treatment of hypertension in 884 patients aged 60 to 79 years at the onset showed a reduction of 18/11 mm Hg in blood pressure over a mean follow up period of 4.4 years. TheExpand
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
TLDR
The data indicate that compared with doxazosin, chlorthalidone reduces the risk of combined CVD events, particularly CHD death/nonfatal MI, in high-risk hypertensive patients. Expand
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.
TLDR
A meta-analysis of double-blind trials that measured the effects of antihypertensive therapy on left ventricular mass found that angiotensin II receptor antagonists, calcium antagonists, and ACE inhibitors were more effective at reducing left Ventricular mass than were beta-blockers. Expand
Beta-blockade in the primary prevention of coronary heart disease in hypertensive patients. Review of present evidence.
TLDR
The aim of this review is to present an overview of the results of randomized primary preventive trials with beta-blockers in patients with hypertension, and to judge, with present evidence, if all beta-blocks are equally effective in preventing sudden death and other coronary events. Expand
...
1
2
3
4
...